A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study

NCT01680536 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

HIV

Interventions

DRUG: maraviroc

Sponsor

St Stephens Aids Trust